Li Yan, Wong Ying Lei, Ng Fui Mee, Liu Boping, Wong Yun Xuan, Poh Zhi Ying, Liu Shuang, Then Siew Wen, Lee Michelle Yueqi, Ng Hui Qi, Huang Qiwei, Hung Alvin W, Cherian Joseph, Hill Jeffrey, Keller Thomas H, Kang CongBao
From the Experimental Therapeutics Centre, Agency for Science, Technology, and Research (A*STAR), 31 Biopolis Way, Nanos, 03-01, Singapore 138669.
From the Experimental Therapeutics Centre, Agency for Science, Technology, and Research (A*STAR), 31 Biopolis Way, Nanos, 03-01, Singapore 138669
J Biol Chem. 2016 Aug 19;291(34):17743-53. doi: 10.1074/jbc.M116.737429. Epub 2016 Jun 30.
Bacterial topoisomerases are attractive antibacterial drug targets because of their importance in bacterial growth and low homology with other human topoisomerases. Structure-based drug design has been a proven approach of efficiently developing new antibiotics against these targets. Past studies have focused on developing lead compounds against the ATP binding pockets of both DNA gyrase and topoisomerase IV. A detailed understanding of the interactions between ligand and target in a solution state will provide valuable information for further developing drugs against topoisomerase IV targets. Here we describe a detailed characterization of a known potent inhibitor containing a 9H-pyrimido[4,5-b]indole scaffold against the N-terminal domain of the topoisomerase IV E subunit from Escherichia coli (eParE). Using a series of biophysical and biochemical experiments, it has been demonstrated that this inhibitor forms a tight complex with eParE. NMR studies revealed the exact protein residues responsible for inhibitor binding. Through comparative studies of two inhibitors of markedly varied potencies, it is hypothesized that gaining molecular interactions with residues in the α4 and residues close to the loop of β1-α2 and residues in the loop of β3-β4 might improve the inhibitor potency.
细菌拓扑异构酶是极具吸引力的抗菌药物靶点,因为它们在细菌生长中起着重要作用,且与其他人类拓扑异构酶的同源性较低。基于结构的药物设计是一种已被证实的有效开发针对这些靶点的新型抗生素的方法。过去的研究主要集中在开发针对DNA促旋酶和拓扑异构酶IV的ATP结合口袋的先导化合物。详细了解溶液状态下配体与靶点之间的相互作用将为进一步开发针对拓扑异构酶IV靶点的药物提供有价值的信息。在此,我们描述了一种已知的含有9H-嘧啶并[4,5-b]吲哚支架的强效抑制剂针对大肠杆菌拓扑异构酶IV E亚基(eParE)N端结构域的详细表征。通过一系列生物物理和生化实验,已证明该抑制剂与eParE形成紧密复合物。核磁共振研究揭示了负责抑制剂结合的确切蛋白质残基。通过对两种效力明显不同的抑制剂的比较研究,推测与α4中的残基、靠近β1-α2环的残基以及β3-β4环中的残基形成分子相互作用可能会提高抑制剂的效力。